The epidemiologic evidence underlying recommendations for use of pneumococcal polysaccharide vaccine among american indian and alaska native populations

Maria A. Said, Katherine L O'Brien, J. Pekka Nuorti, Rosalyn Singleton, Cynthia G. Whitney, Thomas W. Hennessy

Research output: Contribution to journalArticle

Abstract

Alaska Native and some American Indian (AI/AN) populations suffer disproportionately high rates of invasive pneumococcal disease (IPD) in both the pediatric and adult populations compared to the general U.S. population. Two pneumococcal vaccines are currently available in the U.S.: a 23-valent pneumococcal polysaccharide vaccine (PPSV23), available since 1983 and recommended for the elderly and those over 2 years of age with underlying medical conditions, and a 13-valent pneumococcal conjugate vaccine (PCV13), used in the routine infant immunization schedule since 2010. The U.S. Advisory Committee on Immunization Practice (ACIP) previously recommended use of PPSV23 for persons living in special environments or social settings, including AN and certain AI persons 2-64 years of age, on the basis of higher disease rates. The recommendation for routine PPSV23 use among AI/AN persons

Original languageEnglish (US)
Pages (from-to)5355-5362
Number of pages8
JournalVaccine
Volume29
Issue number33
DOIs
StatePublished - Jul 26 2011

Fingerprint

Alaska Natives
Pneumococcal Vaccines
North American Indians
American Indians
polysaccharides
vaccines
immunization
Immunization Schedule
Population
Conjugate Vaccines
Social Environment
Advisory Committees
committees
Immunization
Pediatrics
Pneumovax 23

Keywords

  • 23-Valent pneumococcal polysaccharide vaccine
  • Alaska native
  • American indian
  • Native american
  • Pneumococcus
  • Streptococcus pneumoniae

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

The epidemiologic evidence underlying recommendations for use of pneumococcal polysaccharide vaccine among american indian and alaska native populations. / Said, Maria A.; O'Brien, Katherine L; Nuorti, J. Pekka; Singleton, Rosalyn; Whitney, Cynthia G.; Hennessy, Thomas W.

In: Vaccine, Vol. 29, No. 33, 26.07.2011, p. 5355-5362.

Research output: Contribution to journalArticle

Said, Maria A. ; O'Brien, Katherine L ; Nuorti, J. Pekka ; Singleton, Rosalyn ; Whitney, Cynthia G. ; Hennessy, Thomas W. / The epidemiologic evidence underlying recommendations for use of pneumococcal polysaccharide vaccine among american indian and alaska native populations. In: Vaccine. 2011 ; Vol. 29, No. 33. pp. 5355-5362.
@article{bf04264fa2214c42a8f0ca254b58b459,
title = "The epidemiologic evidence underlying recommendations for use of pneumococcal polysaccharide vaccine among american indian and alaska native populations",
abstract = "Alaska Native and some American Indian (AI/AN) populations suffer disproportionately high rates of invasive pneumococcal disease (IPD) in both the pediatric and adult populations compared to the general U.S. population. Two pneumococcal vaccines are currently available in the U.S.: a 23-valent pneumococcal polysaccharide vaccine (PPSV23), available since 1983 and recommended for the elderly and those over 2 years of age with underlying medical conditions, and a 13-valent pneumococcal conjugate vaccine (PCV13), used in the routine infant immunization schedule since 2010. The U.S. Advisory Committee on Immunization Practice (ACIP) previously recommended use of PPSV23 for persons living in special environments or social settings, including AN and certain AI persons 2-64 years of age, on the basis of higher disease rates. The recommendation for routine PPSV23 use among AI/AN persons",
keywords = "23-Valent pneumococcal polysaccharide vaccine, Alaska native, American indian, Native american, Pneumococcus, Streptococcus pneumoniae",
author = "Said, {Maria A.} and O'Brien, {Katherine L} and Nuorti, {J. Pekka} and Rosalyn Singleton and Whitney, {Cynthia G.} and Hennessy, {Thomas W.}",
year = "2011",
month = "7",
day = "26",
doi = "10.1016/j.vaccine.2011.05.086",
language = "English (US)",
volume = "29",
pages = "5355--5362",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "33",

}

TY - JOUR

T1 - The epidemiologic evidence underlying recommendations for use of pneumococcal polysaccharide vaccine among american indian and alaska native populations

AU - Said, Maria A.

AU - O'Brien, Katherine L

AU - Nuorti, J. Pekka

AU - Singleton, Rosalyn

AU - Whitney, Cynthia G.

AU - Hennessy, Thomas W.

PY - 2011/7/26

Y1 - 2011/7/26

N2 - Alaska Native and some American Indian (AI/AN) populations suffer disproportionately high rates of invasive pneumococcal disease (IPD) in both the pediatric and adult populations compared to the general U.S. population. Two pneumococcal vaccines are currently available in the U.S.: a 23-valent pneumococcal polysaccharide vaccine (PPSV23), available since 1983 and recommended for the elderly and those over 2 years of age with underlying medical conditions, and a 13-valent pneumococcal conjugate vaccine (PCV13), used in the routine infant immunization schedule since 2010. The U.S. Advisory Committee on Immunization Practice (ACIP) previously recommended use of PPSV23 for persons living in special environments or social settings, including AN and certain AI persons 2-64 years of age, on the basis of higher disease rates. The recommendation for routine PPSV23 use among AI/AN persons

AB - Alaska Native and some American Indian (AI/AN) populations suffer disproportionately high rates of invasive pneumococcal disease (IPD) in both the pediatric and adult populations compared to the general U.S. population. Two pneumococcal vaccines are currently available in the U.S.: a 23-valent pneumococcal polysaccharide vaccine (PPSV23), available since 1983 and recommended for the elderly and those over 2 years of age with underlying medical conditions, and a 13-valent pneumococcal conjugate vaccine (PCV13), used in the routine infant immunization schedule since 2010. The U.S. Advisory Committee on Immunization Practice (ACIP) previously recommended use of PPSV23 for persons living in special environments or social settings, including AN and certain AI persons 2-64 years of age, on the basis of higher disease rates. The recommendation for routine PPSV23 use among AI/AN persons

KW - 23-Valent pneumococcal polysaccharide vaccine

KW - Alaska native

KW - American indian

KW - Native american

KW - Pneumococcus

KW - Streptococcus pneumoniae

UR - http://www.scopus.com/inward/record.url?scp=79960360060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960360060&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2011.05.086

DO - 10.1016/j.vaccine.2011.05.086

M3 - Article

VL - 29

SP - 5355

EP - 5362

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 33

ER -